Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120260) titled 'Study on the Role and Mechanism of the Novel Oncolytic Virus VGmiR194-5p in Improving Sorafenib Resistance in Hepatocellular Carcinoma' on March 11.
Study Type: Observational study
Study Design:
Factorial
Primary Sponsor: The First People's Hospital of Fuyang
Condition:
hepatocellular carcinoma
Intervention:
Non-response to treatment group:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-04-01
Target Sample Size: Non-response to treatment group:60;Response to treatment group:60;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showpro...